|
1
|
Park JW, Chen M, Colombo M, Roberts LR,
Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS and
Sherman M: Global patterns of hepatocellular carcinoma management
from diagnosis to death: The bridge study. Liver Int. 35:2155–2166.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wallace MC, Preen D, Jeffrey GP and Adams
LA: The evolving epidemiology of hepatocellular carcinoma: A global
perspective. Expert Rev Gastroenterol Hepatol. 9:765–779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lei C, Ren D, Fu M, Sun C, Ren H, Pan Q
and Li Y: Curative effect of endostar combined with oxaliplatin in
the treatment of primary hepatic carcinoma and its influence on
immune cells. Oncol Lett. 17:3665–3670. 2019.PubMed/NCBI
|
|
4
|
Trépo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar
|
|
5
|
Ichikawa T, Sano K and Morisaka H:
Diagnosis of pathologically early HCC with EOB-MRI: Experiences and
current consensus. Liver Cancer. 3:97–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartke J, Johnson M and Ghabril M: The
diagnosis and treatment of hepatocellular carcinoma. Semin Diagn
Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu ZX, Huang JW, Liao MH and Zeng Y:
Treatment strategy for hepatocellular carcinoma in China:
Radiofrequency ablation versus liver resection. Jpn J Clin Oncol.
46:1075–1080. 2016.PubMed/NCBI
|
|
8
|
Tsurusaki M and Murakami T: Surgical and
locoregional therapy of HCC: TACE. Liver Cancer. 4:165–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raoul JL, Forner A, Bolondi L, Cheung TT,
Kloeckner R and de Baere T: Updated use of TACE for hepatocellular
carcinoma treatment: How and when to use it based on clinical
evidence. Cancer Treat Rev. 72:28–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ito F, Vardam TD, Appenheimer MM, Eng KH,
Gollnick SO, Muhitch JB and Evans SS: In situ thermal ablation
augments antitumor efficacy of adoptive T cell therapy. Int J
Hyperthermia. 36 (Suppl 1):S22–S36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Löffler MW, Nussbaum B, Jäger G,
Jurmeister PS, Budczies J, Pereira PL, Clasen S, Kowalewski DJ,
Mühlenbruch L, Königsrainer I, et al: A non-interventional clinical
trial assessing immune responses after radiofrequency ablation of
liver metastases from colorectal cancer. Front Immunol.
10:25262019. View Article : Google Scholar
|
|
13
|
Zhou J, Sun HC, Wang Z, Cong WM, Wang JH,
Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, et al: Guidelines for
diagnosis and treatment of primary liver cancer in China (2017
edition). Liver Cancer. 7:235–260. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du
X and Liu L: Comparison between child-pugh score and
albumin-bilirubin grade in the prognosis of patients with HCC after
liver resection using time-dependent ROC. Ann Transl Med.
8:5392020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimura S, Odagiri S, Furuya H, Okada K,
Ozawa K, Nagase H, Yamaguchi M and Cho Y: Echocardiography-guided
aortic cannulation by the Seldinger technique for type A dissection
with cerebral malperfusion. J Thorac Cardiovasc Surg. 159:784–793.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi B, Sun A and Zhang X: Influence of
different ex vivo cell culture methods on the proliferation and
anti-tumor activity of cytokine-induced killer cells from gastric
cancer patients. Onco Targets Ther. 11:2657–2672. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonzalez H, Hagerling C and Werb Z: Roles
of the immune system in cancer: from tumor initiation to metastatic
progression. Genes Dev. 32:1267–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu X, Peng M, Huang B, Zhang H, Wang H,
Huang B, Xue Z, Zhang L, Da Y, Yang D, et al: Immune
microenvironment profiles of tumor immune equilibrium and immune
escape states of mouse sarcoma. Cancer Lett. 340:124–133. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quezada SA, Peggs KS, Simpson TR and
Allison JP: Shifting the equilibrium in cancer immunoediting: From
tumor tolerance to eradication. Immunol Rev. 241:104–118. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrari SM, Fallahi P, Galdiero MR,
Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V,
Varricchi G, et al: Immune and Inflammatory Cells in Thyroid Cancer
Microenvironment. Int J Mol Sci. 20:2019. View Article : Google Scholar
|
|
23
|
Ge P, Wang W, Li L, Zhang G, Gao Z, Tang
Z, Dang X and Wu Y: Profiles of immune cell infiltration and
immune-related genes in the tumor microenvironment of colorectal
cancer. Biomed Pharmacother. 118:1092282019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Zhu C, Song W, Li J, Zhao G and
Cao H: PD-L1 expression and CD8(+) T cell infiltration predict a
favorable prognosis in advanced gastric cancer. J Immunol Res.
2018:41805172018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zerbini A, Pilli M, Penna A, Pelosi G,
Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF,
Ferrari C and Missale G: Radiofrequency thermal ablation of
hepatocellular carcinoma liver nodules can activate and enhance
tumor-specific T-cell responses. Cancer Res. 66:1139–1146. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Darvin P, Toor SM, Nair VS and Elkord E:
Immune checkpoint inhibitors: recent progress and potential
biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abril-Rodriguez G and Ribas A: SnapShot:
immune checkpoint inhibitors. Cancer Cell. 31:848–848 e841. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: Results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li
G, Liang J, Hu H, Liu Y, Zhang W and Jiang T: Molecular and
clinical characterization of PD-L1 expression at transcriptional
level via 976 samples of brain glioma. Oncoimmunology.
5:e11963102016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Veloza L, Teixido C, Castrejon N, Climent
F, Carrió A, Marginet M, Soldini D, González-Farré B,
Ribera-Cortada I, Lopez-Guillermo A, et al: Clinicopathological
evaluation of the programmed cell death 1 (PD1)/programmed cell
death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative
disorders: Association with Epstein-Barr virus, PD-L1 copy number
alterations, and outcome. Histopathology. 75:799–812. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara R, Mezquita L, Texier M, Lahmar J,
Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau
S, Le Moulec S, et al: Hyperprogressive disease in patients with
advanced non-small cell lung cancer treated with PD-1/PD-L1
inhibitors or with single-agent chemotherapy. JAMA Oncol.
4:1543–1552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang C, Cao S, Li N, Jiang L and Sun T:
PD-1 and PD-L1 correlated gene expression profiles and their
association with clinical outcomes of breast cancer. Cancer Cell
Int. 19:2332019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie M, Huang X, Ye X and Qian W:
Prognostic and clinicopathological significance of PD-1/PD-L1
expression in the tumor microenvironment and neoplastic cells for
lymphoma. Int Immunopharmacol. 77:1059992019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanna GJ, Woo SB, Li YY, Barletta JA,
Hammerman PS and Lorch JH: Tumor PD-L1 expression is associated
with improved survival and lower recurrence risk in young women
with oral cavity squamous cell carcinoma. Int J Oral Maxillofac
Surg. 47:568–577. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon JH: Adjuvant
immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology. 148:1383–1391.e6. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon JH: Sustained
efficacy of adjuvant immunotherapy with cytokine-induced killer
cells for hepatocellular carcinoma: An extended 5-year follow-up.
Cancer Immunol Immunother. 68:23–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu J, Liu Y, Meng L, Liu K and Ji B:
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib
in human hepatocellular carcinoma. Oncol Rep. 38:899–907. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Naruse T, Yanamoto S, Okuyama K, Ohmori K,
Tsuchihashi H, Furukawa K, Yamada SI and Umeda M:
Immunohistochemical study of PD-1/PD-L1 axis expression in oral
tongue squamous cell carcinomas: Effect of neoadjuvant chemotherapy
on local recurrence. Pathol Oncol Res. 26:735–742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Walcher L, Kistenmacher AK, Suo H, Dluczek
S, Strauß A, Blaudszun AR, Yevsa T, Fricke S and Kossatz-Boehlert
U: Cancer stem cells-origins and biomarkers: Perspectives for
targeted personalized therapies. Front Immunol. 11:12802020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oh SJ, Ahn EJ, Kim O, Kim D, Jung TY, Jung
S, Lee JH, Kim KK, Kim H, Kim EH, et al: The role played by SLUG,
an epithelial-mesenchymal transition factor, in invasion and
therapeutic resistance of malignant glioma. Cell Mol Neurobiol.
39:769–782. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Peng J, Hamanishi J, Matsumura N, Abiko K,
Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et
al: Chemotherapy induces programmed cell death-ligand 1
overexpression via the nuclear factor-κB to foster an
immunosuppressive tumor microenvironment in ovarian cancer. Cancer
Res. 75:5034–5045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baraibar I, Melero I, Ponz-Sarvise M and
Castanon E: Safety and tolerability of immune checkpoint inhibitors
(PD-1 and PD-L1) in cancer. Drug Saf. 42:281–294. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen S, Crabill GA, Pritchard TS, McMiller
TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating
PD-L1 expression on tumor and immune cells. J Immunother Cancer.
7:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M,
Liu LZ, Shi JY, Yang LX, Wang ZC, Zhang S, et al: Clinical
significance of PD-1/PD-Ls gene amplification and overexpression in
patients with hepatocellular carcinoma. Theranostics. 8:5690–5702.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kawahara T, Ishiguro Y, Ohtake S, Kato I,
Ito Y, Ito H, Makiyama K, Kondo K, Miyoshi Y, Yumura Y, et al: PD-1
and PD-L1 are more highly expressed in high-grade bladder cancer
than in low-grade cases: PD-L1 might function as a mediator of
stage progression in bladder cancer. BMC Urol. 18:972018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
D'Alterio C, Nasti G, Polimeno M, Ottaiano
A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De
Divitiis C, et al: CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in
colorectal cancer liver metastases from neoadjuvant-treated
patients. Oncoimmunology. 5:e12543132016. View Article : Google Scholar : PubMed/NCBI
|
